Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-14 · accession 0000950170-25-073746 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-16 | 2025-05-14 | XENE | GANNON STEVEN | Dir | M - OptEx | $12.57 | +5,144 | 7,144 | +257% | +$64.7K |
| D | 2025-05-16 | 2025-05-14 | XENE | GANNON STEVEN | Dir | M - OptEx | $0.00 | -5,144 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-05-14 | M | A | 5,144 | $12.57 | 7,144 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-05-14 | M | D | 5,144 | $0.00 | 0 | D | $12.57 · — to 2025-05-20 | 5,144 Common Shares | (F1) The shares subject to the option are fully vested and exercisable. |